Streptococcus anginosus group

Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022

Retrieved on: 
Wednesday, July 20, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRSA, Patient, Streptococcus agalactiae, MSSA, Streptococcus anginosus group, Bacteria, Food and Drug Administration, Tablet, Culture, Drug of last resort, Marketing, Pyelonephritis, ABSSSI, Review, Staphylococcus aureus, Infection, Streptococcus constellatus, Diarrhea, U.S. Securities and Exchange Commission, Human, Union, Research, Enterococcus, Merck, Moxifloxacin, Streptococcus intermedius, Private Securities Litigation Reform Act, Urinary tract infection, GLOBE, Streptococcus anginosus, Food, COVID-19, Conference, Nausea, Streptococcus pyogenes, Vomiting, Cutis laxa, Linezolid, Fosfomycin, Enterococcus faecalis, Bronchopneumonia, Complicated, Therapy, NASDAQ, Gram, Cystic fibrosis, Pharmaceutical industry, Streptococcus

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026

Retrieved on: 
Thursday, May 5, 2022
MSD, Enterococcus, Drug of last resort, Culture, Neutropenia, NASDAQ, GLOBE, Enterococcus faecalis, MSSA, Streptococcus anginosus group, Merck, Food, Gram, Streptococcus agalactiae, Safety, ABSSSI, CDC, Patient, Streptococcus anginosus, Infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Staphylococcus aureus, Streptococcus pyogenes, MRSA, Marketing, Streptococcus intermedius, Streptococcus constellatus, Growth, Pharmaceutical industry, Vaccine, Streptococcus

Nabriva has been marketing and distributing SIVEXTRO in the United States and certain of its territories as part of an exclusive agreement executed in July 2020 with Merck.

Key Points: 
  • Nabriva has been marketing and distributing SIVEXTRO in the United States and certain of its territories as part of an exclusive agreement executed in July 2020 with Merck.
  • The term of the agreement can be further extended by an additional three-year period, subject to mutual agreement.
  • Ted Schroeder, Chief Executive Officer of Nabriva, commented, We are excited to announce the extension of our agreement with Merck to promote and distribute SIVEXTRO for at least an additional three years.
  • This is a testament to our successful and collaborative relationship with Merck, and our strong commercial performance with SIVEXTRO.

Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)

Retrieved on: 
Monday, September 20, 2021
Biotechnology, FDA, Infectious Diseases, Health, Pharmaceutical, ACT, Therapy, OPPS, Meropenem, Clostridioides, Partial thromboplastin time, Program, MRSA, Minocycline, Staphylococcus aureus, Back pain, Bleeding, Injection, Streptococcus agalactiae, Gram, Genetically modified bacteria, PT, Diarrhea, Center for Medicare and Medicaid Innovation, Food, Regulation of tobacco by the U.S. Food and Drug Administration, MSSA, Methicillin-resistant Staphylococcus aureus, Medicare, Centers for Medicare & Medicaid Services, Adult, Itch, Streptococcus anginosus group, Drug of last resort, Glycopeptide, Elective surgery, Headache, Vomiting, Enterococcus faecalis, Patient, CMS, Limb, Nausea, INR, Warfarin, Risk, Tremor, Streptococcus pyogenes, Chest pain, ASC, Infection, Anaphylaxis, Hypersensitivity, Osteomyelitis, Prospective payment system, Center, Heparin, Chills, Pharmaceutical industry, Hospital, Sales, Vaccine

Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced two important milestones for KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that was launched in July.

Key Points: 
  • Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced two important milestones for KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that was launched in July.
  • We are thrilled to announce these two milestones that will expand reimbursement and access for KIMYRSA, said Christine Ann Miller, Melintas President and Chief Executive Officer.
  • Thats why we intentionally designed KIMYRSA to provide patients with more flexibility and accessibility in ABSSSI treatment.
  • Said John Harlow, Chief Commercial Officer for Melinta, Having a unique J-code for KIMYRSA underscores the distinct value that KIMYRSA brings to the oritavancin franchise.